Case Report| Volume 166, ISSUE 6, P783-787, December 2015

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction

Circulating-free DNA a powerful tool for biomarker testing in advance disease
Published:April 27, 2015DOI:
      PIK3CA gene is frequently mutated in patients with breast cancer and it has been the focus of intense research. Inhibitors of PI3K pathway are being evaluated in ongoing clinical trials but the impact of PIKC3A mutation status on tumor response is yet uncertain. In the metastatic setting, several studies are evaluating the predictive value of PIK3CA mutations. However, results could be biased by biopsy localization. Digital polymerase chain reaction is a new technology that enables detection and quantification of cancer DNA molecules from peripheral blood and can potentially overcome such situation. As a proof of the concept, we present the case of a metastatic patient with a PIK3CA wild-type primary tumor in which the PIK3CA E545K mutation was identified in both the circulating-free DNA obtained from a peripheral blood sample and in the formalin-fixed, paraffin-embedded liver metastasis.


      cfDNA (circulating-free DNA), dPCR (digital polymerase chain reaction), ER (estrogen receptor), PR (progesterone receptor), wt (wild-type)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Stemke-Hale K.
        • Gonzalez-Angulo A.M.
        • Lluch A.
        • et al.
        An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
        Cancer Res. 2008; 68: 6084-6091
        • Banerji S.
        • Cibulskis K.
        • Rangel-Escareno C.
        • et al.
        Sequence analysis of mutations and translocations across breast cancer subtypes.
        Nature. 2012; 486: 405-409
        • Cancer Genome Atlas Network
        Comprehensive molecular portraits of human breast tumours.
        Nature. 2012; 490: 61-70
        • Campbell I.G.
        • Russell S.E.
        • Choong D.Y.
        • et al.
        Mutation of the PIK3CA gene in ovarian and breast cancer.
        Cancer Res. 2004; 64: 7678-7681
        • Kalinsky K.
        • Jacks L.M.
        • Heguy A.
        • et al.
        PIK3CA mutation associates with improved outcome in breast cancer.
        Clin Cancer Res. 2009; 15: 5049-5059
        • Li S.Y.
        • Rong M.
        • Grieu F.
        • Iacopetta B.
        PIK3CA mutations in breast cancer are associated with poor outcome.
        Breast Cancer Res Treat. 2006; 96: 91-95
        • Loi S.
        • Michiels S.
        • Lambrechts D.
        • et al.
        Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
        J Natl Cancer Inst. 2013; 105: 960-967
        • Loibl S.
        • von Minckwitz G.
        • Schneeweiss A.
        • et al.
        PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer.
        J Clin Oncol. 2014; 32: 3212-3220
        • Baselga J.
        • Cortés J.
        • Im S.A.
        • et al.
        Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
        J Clin Oncol. 2014; 32: 3753-3761
        • Hortobagyi G.N.
        • Piccart M.J.
        • Rugo H.S.
        • et al.
        Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. 2013 ASCO Annual Meeting.
        J Clin Oncol. 2013; 31 (suppl; Abstract LBA509)
        • Amir E.
        • Miller N.
        • Geddie W.
        • et al.
        Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.
        J Clin Oncol. 2012; 30: 587-592
        • Dawson S.J.
        • Tsui D.W.
        • Murtaza M.
        • et al.
        Analysis of circulating tumor DNA to monitor metastatic breast cancer.
        N Engl J Med. 2013; 368: 1199-1209
        • Beaver J.A.
        • Jelovac D.
        • Balukrishna S.
        • et al.
        Detection of cancer DNA in plasma of patients with early-stage breast cancer.
        Clin Cancer Res. 2014; 20: 2643-2650
        • Higgins M.J.
        • Jelovac D.
        • Barnathan E.
        • et al.
        Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
        Clin Cancer Res. 2012; 18: 3462-3469
        • Board R.E.
        • Wardley A.M.
        • Dixon J.M.
        • et al.
        Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
        Breast Cancer Res Treat. 2010; 120: 461-467
        • Brennan M.J.
        • Donegan W.L.
        • Appleby D.E.
        The variability of estrogen receptors in metastatic breast cancer.
        Am J Surg. 1979; 137: 260-262
        • Holdaway I.M.
        • Bowditch J.V.
        Variation in receptor status between primary and metastatic breast cancer.
        Cancer. 1983; 52: 479-485
        • Pusztai L.
        • Viale G.
        • Kelly C.M.
        • Hudis C.A.
        Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.
        Oncologist. 2010; 15: 1164-1168
        • Dupont Jensen J.
        • Laenkholm A.V.
        • Knoop A.
        • et al.
        PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
        Clin Cancer Res. 2011; 17: 667-677
        • Schleifman E.B.
        • Desai R.
        • Spoerke J.M.
        • et al.
        Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.
        PLoS One. 2014; 9: e88401
        • Arthur L.M.
        • Turnbull A.K.
        • Renshaw L.
        • et al.
        Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
        Breast Cancer Res Treat. 2014; 147: 211-219
        • Sabine V.S.
        • Crozier C.
        • Brookes C.L.
        • et al.
        Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
        J Clin Oncol. 2014; 32: 2951-2958
        • Crowder R.J.
        • Phommaly C.
        • Tao Y.
        • et al.
        PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
        Cancer Res. 2009; 69: 3955-3962
        • Bachelot T.
        • Bourgier C.
        • Cropet C.
        • et al.
        Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
        J Clin Oncol. 2012; 30: 2718-2724
        • Baselga J.
        • Campone M.
        • Piccart M.
        • et al.
        Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
        N Engl J Med. 2012; 366: 520-529